 "reddy, dr reddy's")
Indian pharmaceutical major Dr Reddy's Laboratories Limited has reported a three-fold increase in consolidated net profit at Rs 312.5 crore for the quarter that ended on March 2017 as compared to Rs 74 crore in the corresponding quarter previous year.
The rise in net profit comes on the back of a substantial decline in operating expenses as well as the lower foreign exchange loss primarily related to its business in Venezuela, besides the lowering of tax expenses. Company's revenues, however, fell by 5 per cent due to lower sales contribution from its North American business.
The consolidated revenues for the quarter under
